ATLANTA — The American Society of Hematology’s annual meeting here has been buzzing about CAR-T therapies. New data show the treatment’s effects can be quite durable — at least for some patients — and suggest that it might be safe to administer some CAR-Ts on an outpatient basis.

For some insight into the early rollout of one of the first CAR-Ts to hit the market, STAT sat down for a quick interview with Dr. David Chang, the chief medical officer of Kite, now a part of Gilead Sciences (GILD).

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy